Last reviewed · How we verify
Second generation antipsychotic
At a glance
| Generic name | Second generation antipsychotic |
|---|---|
| Sponsor | Takeda |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacist-led Interventions in Psychiatric Patients (NA)
- Effect of SC-ICBT for Adults With OCD：A Three-Arm Randomized Controlled Trial (NA)
- Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults (PHASE2)
- Magnetic Seizure Therapy for Psychotic Disorders (NA)
- HD-tDCS for Adolescent Bipolar Depression Targeting S1 (NA)
- Ketogenic and Nutritional Interventions for First Episode Bipolar Disorder (NA)
- Maternal And Infant Antipsychotic Study
- Efficacy and Safety of Paliperidone in Schizophrenia - Bangladesh Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Second generation antipsychotic CI brief — competitive landscape report
- Second generation antipsychotic updates RSS · CI watch RSS
- Takeda portfolio CI